Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study

Thrombosis Research

Volumn 123, Issue 3, 2009, Pages 511-514

  Folkeringa, Nienke ^a   Korteweg, Fleurisca J ^a   Veeger, Nic J G M ^a   Middeldorp, Saskia ^b   Hamulyak, Karly ^c   Prins, Martin H ^c   Erwich, Jan Jaap H M ^a   Büller, Harry R ^b   van der Meer, Jan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fetal loss; Pregnancy; TAFI

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ARTICLE; ENZYME BLOOD LEVEL; FEMALE; FETUS WASTAGE; HUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; CARRIER PROTEINS; COHORT STUDIES; EMBRYO LOSS; FEMALE; FETAL DEATH; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 57849130772     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.02.014     Document Type: Article

References (13)

1. Bajzar L., Manuel R., and Nesheim M.E. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270 (1995) 14477-14484
2. Leebeek F.W., Goor M.P., Guimaraes A.H., Brouwers G.J., Maat M.P., Dippel D.W., et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 3 (2005) 2211-2218
3. van Tilburg N.H., Rosendaal F.R., and Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95 (2000) 2855-2859
4. Middeldorp S. Thrombophilia and pregnancy complications: cause or association?. J Thromb Haemost 5 (2007) 276-282
5. Mousa H.A., Downey C., Alfirevic Z., and Toh C.H. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb Haemost 92 (2004) 1025-1031
6. Bank I., Libourel E.J., Middeldorp S., Hamulyak K., van Pampus E.C., Koopman M.M., et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 3 (2005) 79-84
7. Bank I., Libourel E.J., Middeldorp S., Van Pampus E.C., Koopman M.M., Hamulyak K., et al. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 164 (2004) 1932-1937
8. Lijfering W.M., Coppens M., van de Poel M.H.W., Middeldorp S., Hamulyak K., Bank I., et al. The risk of venous and arterial thrombosis in hyperhomocysteinemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 98 (2007) 457-463
9. Brouwer J.L., Veeger N.J., Kluin-Nelemans H.C., and van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med 145 (2006) 807-815
10. Stirrat G.M. Recurrent miscarriage. Lancet 336 (1990) 673-675
11. Leurs J., and Hendriks D. Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 94 (2005) 471-477
12. Schroeder V., Wilmer M., Buehler B., and Kohler H.P. TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays. Thromb Haemost 96 (2006) 236-237
13. Isermann B., Sood R., Pawlinski R., Zogg M., Kalloway S., Degen J.L., et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nature Med 9 (2003) 331-337